pharma · Acute Ischemic Stroke · Chronic Kidney Disease · DMAC
DiaMedica Therapeutics
DiaMedica Therapeutics is a pharma organization headquartered in Minneapolis, USA. It trades on NYSE under ticker DMAC. Primary therapeutic focus areas include Acute Ischemic Stroke, Chronic Kidney Disease, Diabetes Type
Minneapolis, USA HQ
45 Employees
Public company Type
DMAC · NYSE Ticker
Company details
- Status
- Public
- HQ
- Minneapolis, USA
- Employees
- 45
- Programs
- 8
- Drugs
- 7
- Patents
- 9
DM199
Phase 2 · small molecule · Diabetes Type 2
DM199 for Diabetes Type 2 is a Phase 2 program (small_molecule) at DiaMedica Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code DMA-Clin-199-2013-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- DiaMedica Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Diabetes Type 2
- Status
- completed
- Trials
- 1